SENS 218

Drug Profile

SENS 218

Alternative Names: SENS-218

Latest Information Update: 06 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sensorion
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ear disorders

Most Recent Events

  • 06 Jan 2016 The Medicines and Healthcare products Regulatory Agency approves clinical trial application for phase I trial in Ear disorders
  • 01 Jan 2016 Phase-I clinical trials in Ear disorders (In volunteers) in United Kingdom (Sublingual)
  • 25 Aug 2015 Clinical trials in Ear disorders in France before August 2015 (Sublingual) (Sensorion website, August 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top